Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lynparza Poised To Bring Targeted Therapy To Prostate Cancer

Executive Summary

The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.

You may also be interested in...



Eight Talking Points From ESMO

Proving once again that it is a match for ASCO, here are highlights from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona from 27 September to 1 October.

PROfound Puts Lynparza On Track For Prostate Cancer Indication

AstraZeneca and Merck & Co said their PARP inhibitor Lynparza has become the first to show positive Phase III trial data in metastatic castration-resistant prostate cancer, putting pressure on rival Clovis’s Rubraca.

GSK Embraces PARP Promise With Tesaro Buy

The UK major is marking its return to oncology by spending over $5bn to get hold of Tesaro and its PARP inhibitor Zejula. The question now is whether it will be able to catch AstraZeneca's market-leading Lynparza.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125939

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel